Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 59 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 ESMO Calls for Cancer to Remain a Flagship Priority in the... November 5, 2025 For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... April 15, 2025 Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... December 5, 2022 Load more HOT NEWS Learning to Live With Cancer: A Survivor’s Story A Cancer Revolution: What the experts think of the new Science... Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... 4 Tips from Oncology Dietitians for Healthier Eating During Cancer
